AU2014364930B2 - Micromolded or 3-D printed pulsatile release vaccine formulations - Google Patents

Micromolded or 3-D printed pulsatile release vaccine formulations Download PDF

Info

Publication number
AU2014364930B2
AU2014364930B2 AU2014364930A AU2014364930A AU2014364930B2 AU 2014364930 B2 AU2014364930 B2 AU 2014364930B2 AU 2014364930 A AU2014364930 A AU 2014364930A AU 2014364930 A AU2014364930 A AU 2014364930A AU 2014364930 B2 AU2014364930 B2 AU 2014364930B2
Authority
AU
Australia
Prior art keywords
formulation
antigen
release
bsa
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014364930A
Other languages
English (en)
Other versions
AU2014364930A1 (en
Inventor
William Gates
Ana Jaklenec
Robert S. Langer
Kevin Mchugh
Thanh Duc Nguyen
Boris Nikolic
James J. Norman
Stephany Yi Tzeng
Philip A. Welkhoff
Lowell L. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Tokitae LLC
Original Assignee
Massachusetts Institute of Technology
Tokitae LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Tokitae LLC filed Critical Massachusetts Institute of Technology
Publication of AU2014364930A1 publication Critical patent/AU2014364930A1/en
Application granted granted Critical
Publication of AU2014364930B2 publication Critical patent/AU2014364930B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Micromachines (AREA)
  • Shaping Of Tube Ends By Bending Or Straightening (AREA)
AU2014364930A 2013-12-16 2014-12-16 Micromolded or 3-D printed pulsatile release vaccine formulations Active AU2014364930B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361916555P 2013-12-16 2013-12-16
US61/916,555 2013-12-16
PCT/US2014/070664 WO2015095230A1 (en) 2013-12-16 2014-12-16 Micromolded or 3-d printed pulsatile release vaccine formulations

Publications (2)

Publication Number Publication Date
AU2014364930A1 AU2014364930A1 (en) 2016-07-14
AU2014364930B2 true AU2014364930B2 (en) 2017-06-15

Family

ID=52396804

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014364930A Active AU2014364930B2 (en) 2013-12-16 2014-12-16 Micromolded or 3-D printed pulsatile release vaccine formulations

Country Status (6)

Country Link
US (4) US10300136B2 (https=)
EP (2) EP3082852B1 (https=)
JP (4) JP2017507165A (https=)
AU (1) AU2014364930B2 (https=)
CA (1) CA2933867A1 (https=)
WO (1) WO2015095230A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2933867A1 (en) * 2013-12-16 2015-06-25 Massachusetts Institute Of Technology Micromolded or 3-d printed pulsatile release vaccine formulations
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
WO2018053300A1 (en) * 2016-09-16 2018-03-22 Auburn University Biodegradable polymeric particles encapsulating an active agent, pharmaceutical compositions and uses thereof
US10150282B2 (en) 2016-10-14 2018-12-11 Xerox Corporation System and method for additive manufacture of chemical delivery devices using halftone screening
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
US10933579B2 (en) 2017-03-10 2021-03-02 Prellis Biologics, Inc. Methods and systems for printing biological material
US11085018B2 (en) 2017-03-10 2021-08-10 Prellis Biologics, Inc. Three-dimensional printed organs, devices, and matrices
EP3595515A4 (en) 2017-03-14 2020-12-30 University of Connecticut BIODEGRADABLE PRESSURE SENSOR
JP2020524483A (ja) 2017-05-25 2020-08-20 プレリス バイオロジクス,インク. 三次元印刷された器官、デバイス、およびマトリックス
JP7358340B2 (ja) 2017-05-26 2023-10-10 インフィニット・マテリアル・ソリューションズ,エルエルシー 水溶性ポリマー組成物
CA3231455A1 (en) * 2017-09-13 2019-03-21 Massachusetts Institute Of Technology Microdevices with complex geometries
CN116270513A (zh) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
RU2020132467A (ru) 2018-03-05 2022-04-05 Юниверсити Оф Коннектикут Микроигольная платформа со структурой типа сердцевина-оболочка для трансдермальной и пульсирующей доставки лекарств/вакцин и способ ее изготовления
CA3102755A1 (en) * 2018-06-29 2020-01-02 The Doshisha Formulation containing emricasan
JP7355016B2 (ja) * 2018-07-30 2023-10-03 三菱ケミカル株式会社 熱溶融型積層造形用材料
GB2592486B (en) 2018-07-31 2022-09-14 Prellis Biologics Inc Optically-induced auto-encapsulation
CN110882232B (zh) * 2018-08-20 2026-02-24 中国科学院过程工程研究所 一种基于微囊的疫苗
US11826495B2 (en) 2019-03-01 2023-11-28 University Of Connecticut Biodegradable piezoelectric ultrasonic transducer system
US11678989B2 (en) 2019-03-01 2023-06-20 University Of Connecticut Biodegradable piezoelectric nanofiber scaffold for bone or tissue regeneration
CN110420324B (zh) * 2019-08-01 2022-07-12 临沂大学 含兔葡萄球菌抗原的免疫原性组合物及其制备方法和应用
US11745001B2 (en) 2020-03-10 2023-09-05 University Of Connecticut Therapeutic bandage
US12371581B2 (en) 2020-03-25 2025-07-29 Infinite Material Solutions, Llc High performance water soluble polymer compositions
JP2023522244A (ja) * 2020-04-20 2023-05-29 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 乾燥製剤を生成する方法
MX2022014191A (es) * 2020-05-13 2022-12-07 Massachusetts Inst Technology Composiciones de microdispositivos polimericos y su uso en la inmunoterapia de cancer.
US12491290B2 (en) 2020-06-08 2025-12-09 University Of Connecticut Biodegradable piezoelectric composite materials
CN112370531B (zh) * 2020-11-18 2022-09-23 金宇保灵生物药品有限公司 一种犬瘟热、犬细小、犬腺病毒、犬副流感四联活疫苗耐热保护剂及其制备方法和应用
WO2022192361A2 (en) * 2021-03-09 2022-09-15 Board Of Regents Of The University Of Nebraska Microparticle compositions and methods use thereof
EP4358944A4 (en) * 2021-06-21 2025-03-12 William Marsh Rice University HIGH-YIELD PREPARATION OF PULSATILE-RELEASE MICROPARTICLES
CN113521263A (zh) * 2021-08-03 2021-10-22 苏州大学 一种3d打印的肿瘤疫苗组合物及其制备方法与应用
WO2024026039A2 (en) * 2022-07-27 2024-02-01 Board Of Regents, The University Of Texas System Multi-channeled and guided inner controlling (magic) printheads
WO2024215759A2 (en) * 2023-04-11 2024-10-17 The Regents Of The University Of California Biodegradable scaffolds for enhancing vaccine efficacy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092633A2 (en) * 2002-05-06 2003-11-13 Massachusetts Institute Of Technology Diffusion-controlled dosage form and method of fabrication including three dimensional printing
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
WO2007027273A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
CN103251941A (zh) * 2012-02-16 2013-08-21 海南大学 动物病毒性疫苗脉冲释放系统、其制备方法及用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US5490962A (en) 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
DE69431404T2 (de) 1993-10-22 2003-04-30 Genentech Inc., San Francisco Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
US6312731B1 (en) 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
WO2001026708A1 (en) 1999-10-12 2001-04-19 The Ohio State University Reactive polymeric valve, dispensing devices and methods using same
ATE323470T1 (de) 1999-12-10 2006-05-15 Massachusetts Inst Technology Mikrochip-arzneistoffverabreichungssysteme und herstellungsverfahren
US6565532B1 (en) 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
NZ532096A (en) * 2001-09-28 2006-10-27 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
WO2005046620A2 (en) 2003-11-12 2005-05-26 The General Hospital Corporation Variable appearance tissue markings
US9040090B2 (en) 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
JP5532280B2 (ja) 2003-12-24 2014-06-25 アドゥロ バイオテック 抗原および細菌分泌シグナルポリペプチドを含む融合タンパク質をコードする組換え核酸分子、発現カセット、および細菌、ならびにこれらを使用する方法
EP1708741B1 (en) 2003-12-24 2016-03-30 Aduro Biotech Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006121819A1 (en) 2005-05-06 2006-11-16 Board Of Regents, The University Of Texas System Methods for fabricating nano and microparticles for drug delivery
CA2614927A1 (en) 2005-07-25 2007-02-01 Nanotechnology Victoria Pty Ltd Microarray device
JP5000652B2 (ja) 2005-07-28 2012-08-15 エムフォメーション・テクノロジーズ・インコーポレイテッド ワイヤレス装置のサービス品質管理のためのシステムおよび方法
US20080026040A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
US8349326B2 (en) 2007-02-20 2013-01-08 Tufts University Methods and systems for multi-antibody therapies
CA2700356C (en) 2007-09-27 2013-07-09 Akina, Inc. Sol-gel phase-reversible hydrogel templates and uses thereof
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
WO2009108689A1 (en) 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
JP5702384B2 (ja) 2009-07-31 2015-04-15 スリーエム イノベイティブ プロパティズ カンパニー 中空マイクロニードルアレイ
JP5497176B2 (ja) 2009-08-12 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 圧縮可能な薬品貯槽を備える薬品送出装置
WO2011156641A2 (en) 2010-06-09 2011-12-15 Kaspar Roger L Microneedle arrays for active agent delivery
EP2646051A4 (en) * 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
US20130046182A1 (en) 2011-08-16 2013-02-21 Elwha LLC, a limited liability company of the State of Delaware Devices and Methods for Recording Information on a Subject's Body
CA2875146C (en) 2012-05-30 2022-03-22 The Regents Of The University Of California Bioactive agent delivery devices and methods of making and using the same
US20140200508A1 (en) 2012-06-29 2014-07-17 Isaac D. Cohen Microneedles Comprising One Or More Cosmetic Ingredients
TWI554289B (zh) 2012-06-29 2016-10-21 國立成功大學 鑲嵌式經皮藥物釋放貼片及其製造方法
ITTO20130284A1 (it) 2013-04-09 2014-10-10 Fond Istituto Italiano Di Tecnologia Procedimento per la produzione di microparticelle polimeriche sagomate
EP3021930B1 (en) 2013-07-16 2020-10-07 3M Innovative Properties Company Hollow microneedle with beveled tip
CA2933867A1 (en) * 2013-12-16 2015-06-25 Massachusetts Institute Of Technology Micromolded or 3-d printed pulsatile release vaccine formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
WO2003092633A2 (en) * 2002-05-06 2003-11-13 Massachusetts Institute Of Technology Diffusion-controlled dosage form and method of fabrication including three dimensional printing
WO2007027273A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
CN103251941A (zh) * 2012-02-16 2013-08-21 海南大学 动物病毒性疫苗脉冲释放系统、其制备方法及用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLELAND J L ET AL: "Development of a single-shot subunit vaccine for HIV-1: Part 4. Optimizing microencapsulation and pulsatile release of MN rgp120 from biodegradable microspheres", JOURNAL OF CONTROLLED RELEASE, vol. 47 (1997) pgs 135-150 *
CLELAND J L: "Single-administration vaccines: controlled-release technology to mimic repeated immunizations", TRENDS IN BIOTECHNOLOGY, vol. 17 (1999) pages 25-29 *
NUXOLL E: "BioMEMS in drug delivery", ADVANCED DRUG DELIVERY REVIEWS, vol. 65 (2013)pages 1611-1625 *
SANCHEZ A ET AL: "PULSED CONTROLLED-RELEASE SYSTEM FOR POTENTIAL USE IN VACCINE DELIVERY", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 85, no. 6 (1996) pages 547-552 *

Also Published As

Publication number Publication date
JP7682019B2 (ja) 2025-05-23
EP3763383A1 (en) 2021-01-13
WO2015095230A1 (en) 2015-06-25
EP3082852B1 (en) 2020-06-17
JP2023075311A (ja) 2023-05-30
US20150165020A1 (en) 2015-06-18
JP2017507165A (ja) 2017-03-16
US20190328871A1 (en) 2019-10-31
JP2020055818A (ja) 2020-04-09
JP2021120413A (ja) 2021-08-19
EP3082852A1 (en) 2016-10-26
US10300136B2 (en) 2019-05-28
US10960073B2 (en) 2021-03-30
US20240181047A1 (en) 2024-06-06
CA2933867A1 (en) 2015-06-25
US20210205444A1 (en) 2021-07-08
US11975069B2 (en) 2024-05-07
AU2014364930A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
US20240181047A1 (en) Micromolded or 3-d printed pulsatile release vaccine formulations
Kim et al. Microspheres for drug delivery
US20210290921A1 (en) Microdevices with complex geometries
Mao et al. Recent advances in polymeric microspheres for parenteral drug delivery—part 2
Hajavi et al. Optimization of PLGA formulation containing protein or peptide‐based antigen: recent advances
Hou et al. Up-to-date vaccine delivery systems: robust immunity elicited by multifarious nanomaterials upon administration through diverse routes
Johansen et al. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs
Diesner et al. Use of lectin-functionalized particles for oral immunotherapy
Kaur et al. Polymer particulates in drug delivery
Park et al. Microencapsulation technology
Zhao et al. Implantable microarray patch: engineering at the nano and macro scale for sustained therapeutic release via synthetic biodegradable polymers
US20110163469A1 (en) High-throughput fabrication of microparticles
D’Mello et al. Polymeric nanoparticles for small-molecule drugs: biodegradation of polymers and fabrication of nanoparticles
CA2364198A1 (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
Takada Microfabrication derived DDS: From batch to individual production
Nechaeva Development of oral microencapsulated forms for delivering viral vaccines
More et al. An overview: use of polymer microspheres in controlled drug delivery
D’Mello et al. Polymeric nanoparticles for small-molecule drugs: biodegradation of polymers and fabrication of nanoparticles
Schiller Scalable processes to manufacture nanoparticulate dosage forms for oral vaccination
Jit et al. Microsphere in Novel Drug Delivery System-A Descriptive Review
Pal et al. Drug Delivery to the Immune System: Immunotherapies and Vaccines
Lahane et al. Role of Nanoparticle Formulation for the Combination Delivery of Multiple Antigens
Yeo et al. Recent advances in microencapsulation technology
Guan Fabrication of polymeric microparticles for drug delivery
Kaur et al. Particulates: Drug Delivery

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ JAKLENEC, ANA; GATES, WILLIAM; ECKHOFF, PHILIP A.; NIKOLIC, BORIS; WOOD, LOWELL L.; LANGER, ROBERT S.; NGUYEN, THANH DUC; TZENG, STEPHANY YI; NORMAN, JAMES J. AND MCHUGH, KEVIN

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ JAKLENEC, ANA; GATES, WILLIAM; ECKHOFF, PHILIP A.; NIKOLIC, BORIS; WOOD, LOWELL L.; LANGER, ROBERT S.; NGUYEN, THANH DUC; TZENG, STEPHANY YI; NORMAN, JAMES J. AND MCHUGH, KEVIN

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ JAKLENEC, ANA; GATES, WILLIAM; WELKHOFF, PHILIP A.; NIKOLIC, BORIS; WOOD, LOWELL L.; LANGER, ROBERT S.; NGUYEN, THANH DUC; TZENG, STEPHANY YI; NORMAN, JAMES J. AND MCHUGH, KEVIN